共有 1 页
品牌 | 货号 | 包装单位 | 货期 | 产品名称 | 质量规格 | 单价(¥) | 购买数量 |
---|---|---|---|---|---|---|---|
罗恩 | R028216-5mg | 5mg | 现货 |
3-氨基-6-[4-(甲基磺酰基)苯基]-N-苯基-2-... 3-Amino-6-[4-(methylsulfonyl... |
99% |
|
|
罗恩 | R028216-25mg | 25mg | 现货 |
3-氨基-6-[4-(甲基磺酰基)苯基]-N-苯基-2-... 3-Amino-6-[4-(methylsulfonyl... |
99% |
|
|
阿拉丁 | V125220-5mg | 5mg | 现货 |
VE-821,ATR抑制剂 VE-821 |
Moligand™, ≥98% |
|
|
阿拉丁 | V125220-25mg | 25mg | 现货 |
VE-821,ATR抑制剂 VE-821 |
Moligand™, ≥98% |
|
|
阿拉丁 | V125220-100mg | 100mg | 现货 |
VE-821,ATR抑制剂 VE-821 |
Moligand™, ≥98% |
|
|
阿拉丁 | V408304-1ml | 1ml | 现货 |
VE-821 VE-821 |
Moligand™, 10mM in DMSO |
|
|
凯为 | JZ000L85-100mg | 100mg | 现货 |
3-氨基-6-[4-(甲基磺酰基)苯基]-N-苯基-2-... 2-Pyrazinecarboxamide, 3-ami... |
98% |
|
|
凯为 | JZ000L85-250mg | 250mg | 现货 |
3-氨基-6-[4-(甲基磺酰基)苯基]-N-苯基-2-... 2-Pyrazinecarboxamide, 3-ami... |
98% |
|
|
凯为 | JZ000L85-1g | 1g | 现货 |
3-氨基-6-[4-(甲基磺酰基)苯基]-N-苯基-2-... 2-Pyrazinecarboxamide, 3-ami... |
98% |
|
|
凯为 | JZ000L85-5mg | 5mg | 现货 |
3-氨基-6-[4-(甲基磺酰基)苯基]-N-苯基-2-... 2-Pyrazinecarboxamide, 3-ami... |
98% |
|
|
凯为 | JZ000L85-25mg | 25mg | 现货 |
3-氨基-6-[4-(甲基磺酰基)苯基]-N-苯基-2-... 2-Pyrazinecarboxamide, 3-ami... |
98% |
|
|
毕得 | BD305204-10mg | 10mg | 现货 |
3-氨基-6-[4-(甲基磺酰基)苯基]-N-苯基-2-... 3-Amino-6-(4-(methylsulfonyl... |
99% (HPLC) |
|
|
毕得 | BD305204-50mg | 50mg | 现货 |
3-氨基-6-[4-(甲基磺酰基)苯基]-N-苯基-2-... 3-Amino-6-(4-(methylsulfonyl... |
99% (HPLC) |
|
|
毕得 | BD305204-100mg | 100mg | 现货 |
3-氨基-6-[4-(甲基磺酰基)苯基]-N-苯基-2-... 3-Amino-6-(4-(methylsulfonyl... |
99% (HPLC) |
|
|
毕得 | BD305204-250mg | 250mg | 现货 |
3-氨基-6-[4-(甲基磺酰基)苯基]-N-苯基-2-... 3-Amino-6-(4-(methylsulfonyl... |
99% (HPLC) |
|
|
毕得 | BD305204-1g | 1g | 现货 |
3-氨基-6-[4-(甲基磺酰基)苯基]-N-苯基-2-... 3-Amino-6-(4-(methylsulfonyl... |
99% (HPLC) |
|
|
梯希爱 | V0206-25MG | 25MG | 现货 |
3-氨基-6-[4-(甲基磺酰基)苯基]-N-苯基-2-... VE-821 |
95.0% |
|
|
梯希爱 | V0206-5MG | 5MG | 现货 |
3-氨基-6-[4-(甲基磺酰基)苯基]-N-苯基-2-... VE-821 |
95.0% |
|
|
阿法埃莎 | C46789-100MG | 100MG | 现货 |
VE-821, 95% VE-821, 95% |
|
|
|
Acros | 467891000 | 100MG | 现货 |
VE-821, 95% VE-821, 95% |
|
|
|
百灵威 | JK1564473-5MG | 5MG | 1天 |
VE-821 VE-821, 99%, a potent ATP-c... |
99% |
|
|
百灵威 | JK1564473-10MG | 10MG | 1天 |
VE-821 VE-821, 99%, a potent ATP-c... |
99% |
|
|
Sigma | SML1415-5MG | 5mg | 请咨询 |
(-20°C)VE-821 VE-821 |
咨询 | 请联系客服购买! | |
Sigma | SML1415-25MG | 25mg | 请咨询 |
(-20°C)VE-821 VE-821 |
咨询 | 请联系客服购买! | |
源叶 | S80205-2mg | 2mg | 现货 |
VE-821 VE-821 |
99% |
|
|
源叶 | S80205-5mg | 5mg | 现货 |
VE-821 VE-821 |
99% |
|
|
源叶 | S80205-10mg | 10mg | 现货 |
VE-821 VE-821 |
99% |
|
|
源叶 | S80205-25mg | 25mg | 现货 |
VE-821 VE-821 |
99% |
|
|
源叶 | S80205-50mg | 50mg | 现货 |
VE-821 VE-821 |
99% |
|
|
源叶 | S80205-100mg | 100mg | 现货 |
VE-821 VE-821 |
99% |
|
|
源叶 | T95388-1ml | 1ml | 期货,请咨询 |
VE-821 VE-821 |
10mM in DMSO |
|
|
Target Mol | T3032-5mg | 5mg | 现货 |
化合物 VE-821 VE-821 |
99.97% |
|
|
Target Mol | T3032-10mg | 10mg | 现货 |
化合物 VE-821 VE-821 |
99.97% |
|
|
Target Mol | T3032-25mg | 25mg | 现货 |
化合物 VE-821 VE-821 |
99.97% |
|
|
Target Mol | T3032-50mg | 50mg | 现货 |
化合物 VE-821 VE-821 |
99.97% |
|
|
Target Mol | T3032-100mg | 100mg | 现货 |
化合物 VE-821 VE-821 |
99.97% |
|
|
Target Mol | T3032-1mL | 1mL | 现货 |
化合物 VE-821 VE-821 |
99.97% |
|
|
Combi | QK-7593-100mg | 100mg | 请咨询 |
3-Amino-6-(4-methanesulfonyl... 3-Amino-6-(4-methanesulfonyl... |
95% | 咨询 | 请联系客服购买! |
Am | A312952-5mg | 5mg | 现货 |
VE-821 VE-821 |
98+% |
|
|
Am | A312952-50mg | 50mg | 现货 |
VE-821 VE-821 |
98+% |
|
|
Am | A312952-10mg | 10mg | 现货 |
VE-821 VE-821 |
98+% |
|
|
Am | A312952-1mg | 1mg | 现货 |
VE-821 VE-821 |
98+% |
|
|
Am | A312952-25mg | 25mg | 现货 |
VE-821 VE-821 |
98+% |
|
|
Am | A312952-100mg | 100mg | 现货 |
VE-821 VE-821 |
98+% |
|
|
MCE | HY-14731-100mg | 100mg | 现货 |
VE-821 VE-821 |
98.32% |
|
|
MCE | HY-14731-50mg | 50mg | 现货 |
VE-821 VE-821 |
98.32% |
|
|
MCE | HY-14731-25mg | 25mg | 现货 |
VE-821 VE-821 |
98.32% |
|
|
MCE | HY-14731-10mg | 10mg | 现货 |
VE-821 VE-821 |
98.32% |
|
|
MCE | HY-14731-10mM*1mL | 10mM*1mL | 现货 |
VE-821 VE-821 |
98.32% |
|
|
MCE | HY-14731-5mg | 5mg | 现货 |
VE-821 VE-821 |
98.32% |
|
|
MCE | HY-14731-1mg | 1mg | 现货 |
VE-821 VE-821 |
98.32% |
|
|